Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 to 70

Dexmedetomidine added to a nerve block for middle ear surgery

Official title: Efficacy of Dexmedetomidine as an Adjuvant to Ultrasound-Guided Greater Auricular Nerve Block for Middle Ear Surgeries: A Randomized Double-Blinded Controlled Study

Run by Minia University · NCT07878533 · Data updated 2026-11-12

In adults having elective middle ear surgery, this trial tests whether adding dexmedetomidine to bupivacaine for a greater auricular nerve block can extend pain relief after surgery.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment40 (estimated)
SponsorMinia University
Academic / other
Locations1 site (Minya)
StatusRecruiting
StartedSeptember 25, 2026
Main results expectedApril 30, 2027
Study endsMay 30, 2027
Registry record updatedOctober 16, 2026
Trial IDNCT07878533 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18-70 years undergoing elective middle ear surgery under general anesthesia, ASA I-II, BMI ≤ 35 kg/m2.

Probably not a fit

Patients who do not experience extended analgesia or who have adverse reactions to dexmedetomidine may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double-blind, controlled Phase 2 trial comparing two nerve block regimens given under ultrasound guidance before anesthesia induction. One group receives bupivacaine alone, the other receives bupivacaine plus dexmedetomidine, with all patients receiving standard general anesthesia and a uniform rescue analgesia plan. Outcomes tracked include duration of analgesia, pain scores, opioid consumption, emergence agitation, hemodynamics, and adverse effects over 24 hours postoperatively. The study uses computer-generated randomization and sealed envelopes, with outcome assessors blinded to group allocation. Forty adults with ASA I-II undergoing elective middle ear surgery are enrolled.

Why it matters

Potential benefit: If successful, the dexmedetomidine adjuvant could prolong pain relief and reduce opioid needs after middle ear surgery.

How similar studies have gone: Previous work in regional anesthesia has shown that dexmedetomidine can prolong block duration in various nerve blocks, suggesting potential for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Inclusion Criteria:
* Patients scheduled for elective middle ear surgery under general anesthesia
* Aged 18-70 years
* ASA physical status I or II
* BMI ≤ 35 kg/m2

Exclusion Criteria:

* Patient refusal
* Known allergy to local anesthetics or dexmedetomidine
* Coagulation disorders or anticoagulant therapy
* Infection at the injection site
* History of head and neck surgery
* Significant cardiovascular disease (heart block, severe bradycardia, or uncontrolled hypertension)
* Hepatic or renal impairment
* Chronic opioid or analgesic use
* Psychiatric disorders or inability to cooperate
* Pregnancy or lactation

Where it's running

  • Minia university hospital
    Minya, Egypt
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.